From: Emerging therapies in advanced hepatocellular carcinoma
NCT number | Treatment | Target | Outcome | Phase |
---|---|---|---|---|
NCT02702401 | Pembrolizumab vs best supportive care | PD-1 | PFS, OS | Phase III |
NCT02576509 | Nivolumab vs sorafenib | PD-1 | OS | Phase III |
NCT02519348 | Durvalumab + tremelimumab vs durvalumab monotherapy | PD-L1/CTLA-4 | Adverse events | Phase II |
NCT03298451 | Durvalumab vs durvalumab + tremelimumab vs sorafenib HIMALAYA | PD-L1/CTLA-4 | OS | Phase III |
NCT01658878 | Nivolumab vs nivolumab + ipilimumab vs sorafenib | PD-L1/CTLA-4 | ORR | Phase I/II |